Is serum amyloid A a novel prognostic biomarker in hepatocellular carcinoma?
High SAA serum level is a novel biomarker for the prognosis of HCC patients.
The findings provide evidence that among the lesions with varying disease burden at diagnosis, the FDG uptake is highest in cases with both axillary and distant metastasis, followed by those with axillary metastasis and then by those with no metastatic disease. These provide in vivo insight into tumor biology as FDG uptake is regarded as a surrogate marker of the same.